Primary prevention of cardiotoxicity in cancer patients treated with fluoropyrimidines: a randomized controlled trial.

ABSTRACT:

Background

Fluoropyrimidines (FP) are the third most used chemotherapeutic drugs administered in solid tumors but have cardiotoxic side effects. We aimed to determine whether pre-chemotherapeutic cardiological assessment and management of cardiovascular risk factors could prevent FP-induced cardiotoxicity and if the coronary artery calcium (CAC) score was predictive of chest pain.

Methods

This was a randomized, controlled, single center trial of patients with various cancer types who were treated with FP and had no known ischemic heart disease. All patients had CAC score obtained by cardiac CT scan. Patients were randomized to pre-chemotherapeutic cardiological management or standard care. Cardiological management included risk reduction based on electro- and echocardiograph

SUBMITTER: Lyhne JD 

PROVIDER: S-EPMC12084922 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature